Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Bristol-Myers Squibb describes preclinical profile of apelin receptor agonist BMS-986224

Sep. 6, 2019

Applied Therapeutics begins phase III study of AT-1001 for diabetic cardiomyopathy

Sep. 5, 2019

Fulacimstat does not improve standard of care treatment in CHIARA MIA 2 study

Sep. 4, 2019

BMS-986235 shows efficacy in preclinical models of heart failure

Sep. 4, 2019

eXIthera Pharmaceuticals divulges coagulation factor XIa and kallikrein inhibitors

Sep. 3, 2019

UCn2 gene transfer improves diabetes-related left-ventricular dysfunction in mice

Sep. 3, 2019

First preclinical data presented on miR-132 inhibitor CDR132L in heart failure model

Sep. 3, 2019

Phase II data reported for P2Y12 inhibitor selatogrel in CAD patients

Sep. 2, 2019

La Jolla Pharmaceutical receives European approval for Giapreza

Aug. 30, 2019

MyoKardia initiates dosing in phase I study of MYK-224 for hypertrophic cardiomyopathy

Aug. 22, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...